VERAXA Biotech (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
These findings further validate the potential of the BiTAC-ADC platform and complement VERAXA's BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The full press release is available at https://ibn.fm/QiPhH.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The proof-of-concept data underscores the potential of the BiTAC-ADC platform to address key challenges in cancer therapy, such as off-target toxicity and limited efficacy against solid tumors. By using two separately delivered components that only become active in the tumor microenvironment, the platform aims to enhance the therapeutic window for potent anticancer agents. This approach could lead to treatments that are both more effective and safer for patients.
Investors and industry observers will be watching for further developments from VERAXA, particularly as the company seeks partnerships to advance its platforms. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
